Antibody–Drug Conjugates—Evolution and Perspectives
International Journal of Molecular Sciences · 26.06.2024 · 25 (13) · 6969
DOI: 10.3390/ijms25136969 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 26.06.2024. Verfasst von Adriana Aurelia Chis und 10 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, "Lucian Blaga" University of Sibiu, 550169 Sibiu, Romania. Hauptthemen laut MEDLINE: Immunoconjugates, Neoplasms. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 176 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: LBUS-IRG-2023, Lucian Blaga University of Sibiu.
Abstract (Originalsprache)
Antineoplastic therapy is one of the main research themes of this century. Modern approaches have been implemented to target and heighten the effect of cytostatic drugs on tumors and diminish their general/unspecific toxicity. In this context, antibody–drug conjugates (ADCs) represent a promising and successful strategy. The aim of this review was to assess different aspects regarding ADCs. They were presented from a chemical and a pharmacological perspective and aspects like structure, conjugation and development particularities alongside effects, clinical trials, safety issues and perspectives and challenges for future use of these drugs were discussed. Representative examples include but are not limited to the following main structural components of ADCs: monoclonal antibodies (trastuzumab, brentuximab), linkers (pH-sensitive, reduction-sensitive, peptide-based, phosphate-based, and others), and payloads (doxorubicin, emtansine, ravtansine, calicheamicin). Regarding pharmacotherapy success, the high effectiveness expectation associated with ADC treatment is supported by the large number of ongoing clinical trials. Major aspects such as development strategies are first discussed, advantages and disadvantages, safety and efficacy, offering a retrospective insight on the subject. The second part of the review is prospective, focusing on various plans to overcome the previously identified difficulties.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, "Lucian Blaga" University of Sibiu, 550169 Sibiu, Romania.
- Faculty of Agriculture Science, Food Industry and Environmental Protection, "Lucian Blaga" University of Sibiu, 550012 Sibiu, Romania.
ORCID-Profile: Adriana Aurelia Chis, Carmen Maximiliana Dobrea, Anca Maria Arseniu, Adina Frum, Luca-Liviu Rus, Cecilia Georgescu, Claudiu Morgovan, Anca Butuca, Felicia Gabriela Gligor, Andreea Loredana Vonica-Tincu
Förderung
- LBUS-IRG-2023
- Lucian Blaga University of Sibiu
Zitieren
APA
Chis, A. A., Dobrea, C. M., Arseniu, A. M., Frum, A., Rus, L. L., Cormos, G., Georgescu, C., Morgovan, C., Butuca, A., Gligor, F. G., & Vonica-Tincu, A. L. (2024). Antibody–Drug Conjugates—Evolution and Perspectives. International Journal of Molecular Sciences, 25(13), 6969. https://doi.org/10.3390/ijms25136969
Vancouver
Chis AA, Dobrea CM, Arseniu AM, Frum A, Rus LL, Cormos G, et al. Antibody–Drug Conjugates—Evolution and Perspectives. International Journal of Molecular Sciences. 2024;25(13):6969. doi:10.3390/ijms25136969
BibTeX
@article{Chis2024,
author = {Chis, Adriana Aurelia and Dobrea, Carmen Maximiliana and Arseniu, Anca Maria and Frum, Adina and Rus, Luca-Liviu and Cormos, Gabriela and Georgescu, Cecilia and Morgovan, Claudiu and Butuca, Anca and Gligor, Felicia Gabriela and Vonica-Tincu, Andreea Loredana},
title = {Antibody–Drug Conjugates—Evolution and Perspectives},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {13},
pages = {6969},
doi = {10.3390/ijms25136969}
}
EUVIMED